Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.

In this first case series of ocular adverse effects after brolucizumab 6 mg injection at a single tertiary care center, the incidence of ocular adverse effects was 3.5%, including a 2.6% incidence of intraocular inflammation.